Chase Therapeutics
Chase Therapeutics: An early-stage pharmaceutical company innovating superior brain disease treatments.
- 175
- Series B
Chase Therapeutics is an early-stage pharmaceutical company dedicated to developing superior treatments for brain diseases. Their mission is to innovate and improve therapeutic options for neurological conditions, addressing a significant market need for more effective solutions. The company focuses on creating product-based therapies that offer better outcomes for patients suffering from various brain disorders.
Chase Therapeutics has made notable strides in the pharmaceutical industry, contributing to advancements in brain disease treatment. Their efforts have garnered attention and support from key stakeholders in the medical and investment communities. The company's impact is reflected in its commitment to enhancing patient care through cutting-edge research and development.
Similar Companies

Woolsey Pharmaceuticals
woolseypharma.com

Chesapeake Therapeutics

Aria Pharmaceuticals

NeuroPro Therapeutics

PleoPharma
pleopharma.com

Engrail Therapeutics
engrail.com

Courage Therapeutics
couragetx.com

MapLight Therapeutics
maplightrx.com

Xoc Pharmaceuticals

Escape Bio
escapebio.com

Evon Medics
evonmedics.com

Cerebral Therapeutics
BlackThorn Therapeutics

AimMax Therapeutics
aimmaxrx.com

Camino Pharma
caminopharma.com
Quick Facts
Who are Chase Therapeutics' competitors?
Companies similar to Chase Therapeutics include Woolsey Pharmaceuticals, Chesapeake Therapeutics, Aria Pharmaceuticals and NeuroPro Therapeutics.
When was Chase Therapeutics founded?
Chase Therapeutics was founded in 2017.
Where is Chase Therapeutics' headquarters located?
Chase Therapeutics' headquarters is located in Washington, DC, US.
When was Chase Therapeutics' last funding round?
Chase Therapeutics' most recent funding round was for $20M (USD) in October 2021.
How much disclosed funding has Chase Therapeutics raised?
As of Oct 20, 2021, Chase Therapeutics has disclosed funding of $25.3M (USD). Undisclosed round amounts are excluded.
How many employees does Chase Therapeutics have?
Chase Therapeutics has 175 employees as of Feb 5, 2024.
Classification
- Ownership
- Technology
- Geographic Exposure
- Customer
- Main Product
- Tags
- NAICS
- 620000Health Care and Social Assistance
- 623000Nursing and Residential Care Facilities
- SIC
- 8000Health Services
- 8040Offices And Clinics Of Other Health Practitioners
- 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
Show 16 more industry codes
- NAICS
- 320000Manufacturing
- 325400Pharmaceutical and Medicine Manufacturing
- 540000Professional, Scientific, and Technical Services
- 541714Research and Development in Biotechnology (except Nanobiotechnology)
- 325000Chemical Manufacturing
- 541000Professional, Scientific, and Technical Services
- 541700Scientific Research and Development Services
- 325410Pharmaceutical and Medicine Manufacturing
- 541710Research and Development in the Physical, Engineering, and Life Sciences
- 325412Pharmaceutical Preparation Manufacturing
- SIC
- 2800Chemicals And Allied Products
- 8700Engineering, Accounting, Research, Management, And Related Services
- 2830Drugs
- 8730Research, Development, And Testing Services
- 2834Pharmaceutical Preparations
- 8731Commercial Physical and Biological Research